- Home
- / Boston Scientific
- / Financials
Boston ScientificHeader placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Financial statements
| USD | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|
| Revenue | 10.7B | 9.9B | 11.9B |
| Revenue growth, % | 9.3% | -7.7% | |
| Cost of goods sold | 3.1B | 3.5B | 3.7B |
| Gross profit | 7.6B | 6.4B | 8.2B |
| Gross profit margin, % | 71.0% | 65.0% | 68.8% |
| General and administrative expense | 3.9B | 3.8B | 4.4B |
| Operating expense total | 6.1B | 6.5B | 7.0B |
| Depreciation and amortization | 699.0M | 789.0M | 741.0M |
| EBIT | 1.5B | (80.0M) | 1.2B |
| EBIT margin, % | 14.1% | -0.8% | 10.1% |
| Interest income | 30.0M | ||
| Interest expense | 473.0M | 361.0M | 341.0M |
| Pre tax profit | 687.0M | (79.0M) | 1.1B |
| Income tax expense | (4.0B) | 2.0M | 36.0M |
| Net Income | 4.7B | (82.0M) | 1.0B |
| EPS | 3.3 | (0.1) | 0.7 |